- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Almac Plans 500 New Jobs for Northern Ireland
30 September 2009
Research, development and manufacturing company Almac (Northern Ireland) has secured permission for "major expansion plans" that could lead to the creation of over 500 jobs during the next five years. The company has acquired a 5.4 acre site adjacent to its Craigavon headquarters and will shortly embark on the first phase of development there. Last year, its UK staff numbers rose by 15% to 1,426 and US staff by 10% to 762.
Group Chairman Sir Allen McClay said: "This is an exciting time for Almac. Since our foundation in 2001 we have grown at record levels, and we expect this trend to continue over the coming years. With our rapid rate of growth it was important to put proper plans in place and provide the necessary room for Almac to expand."
The company is also presently engaged in construction of its new $112 million North American Headquarters.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
